Document:

Supply and Distribution Agreement between the Registrant and Soering, GmbH

 Exhibit 10.18 
 SUPPLY AND DISTRIBUTION AGREEMENT 
 THIS AGREEMENT is made and effective the 10, October 2005
(“Effective Date”) between TissueLink Medical, Inc., a Delaware corporation having a place of business at One Washington Center, Suite 400, Dover, NH 03820, USA (“TLM”); and Soering, GmbH, a Germany company having a place of
business at Justus-von-Liebig-Ring 2, D-25451, Quickborn, Germany (“SOERING”). 
 WITNESSETH 
 WHEREAS, SOERING designs, develops, manufactures and sells bipolar electro surgery systems; 
 WHEREAS, TLM designs, develops, manufactures and markets medical devices; 
 WHEREAS, TLM and SOERING entered into a certain Development Agreement dated as of January 10, 2005 (the “Development Agreement”) pursuant to which they collaborated to the development of certain
products. 
 WHEREAS, as a result of the collaboration under the Development Agreement, SOERING desires to manufacture and supply to TLM
certain products, which are more fully described in Schedule A, as the same may be amended or supplemented from time to time by an instrument executed on behalf of each of SOERING and TLM (the Products”), all in accordance with the terms and
conditions set forth herein; and 
 WHEREAS, TLM desires to purchase Products from SOERING and distribute the Products throughout the world.

 NOW, THEREFORE, in consideration of the foregoing and the mutual covenants and agreements contained herein and intending to be legally
bound, the parties agree as follows: 
 SECTION I. SUPPLY AGREEMENT 
  

	 	1.	Supply Requirements. 

 1.1. TLM agrees to purchase from
SOERING and SOERING agrees to sell to TLM the Products on the terms set forth in this Agreement. 
 1.2. (a) SOERING shall deliver to TLM, for
TLM’s inspection, a reasonable number of preproduction quality samples of each of the Products (“Inspection Samples”) as agreed upon by the parties, which conform to the specifications, consisting in the case of the Products
designated as the Generator Product thereon (the “Generator Product”) of the relevant manufacturing specifications and subsidiary detail specifications and drawings agreed upon by TLM and SOERING (“Specifications”), including
reports documenting that the Products have been inspected and tested. 
  

 1 
 [*] =
Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. 

 (b) TLM shall provide to SOERING any objections it has concerning the conformance of the Inspection
Samples to the Specifications within thirty (30) days after receipt of the Inspection Samples (the “Inspection Period”) and SOERING shall make such changes to Products prior to production. If no objections are identified by TLM during
the Inspection Period, the Inspection Samples shall be deemed acceptable by TLM. The Inspection Period for the Inspection Samples of the initial Products covered by this Agreement (that are listed in Schedule A on the Effective Date) shall be known
as the “Initial Inspection Period”. 
 1.3. On or prior to the end of the Initial Inspection Period, TLM shall deliver to SOERING a
forecast (“Forecast”) of TLM’s requirements for Products during the initial twelve-month period after the Initial Inspection Period as listed in attached Schedule C. On or before the last day of each month after the Initial Inspection
Period and during the term of this Agreement, TLM shall deliver to SOERING a six-month rolling Forecast of TLM’s requirements for Products. Each forecast shall specify the quantities of each Product and the projected shipment dates therefor.
The first three months of the initial six-month Forecast shall represent TLM’s binding purchase order for the quantities of Products specified therein. For each six-month rolling Forecast thereafter, the third month of such rolling Forecast
shall be TLM’s binding purchase order for the quantities specified therein. SOERING shall not be obligated to supply quantities of Products in excess of those quantities subject to binding purchase orders. SOERING, however, shall use its
commercially reasonable efforts to deliver to TLM, pursuant to purchase orders, quantities of Products even if TLM has modified a projection of Product requirements for such quantities. 
 1.4. It is understood that the terms of this Agreement shall supersede any conflicting terms of purchase orders for all purchases of Products.

 1.5. TLM and SOERING have agreed upon the minimum purchase requirements (the “Initial Products Minimum”) for the first twelve
(12) months for the Generator Product: As shown in Schedule C. 
  

	 	2.	Prices and Payment. 

 2.1. Pricing of Products shall be
according to the terms set forth in Schedule B attached hereto. 
 2.2. Upon the request of either party, the parties shall negotiate in good
faith during the first two months of the fourth quarter of each subsequent year with respect to changes in the pricing of Products to be effective on the first day of the second year and of each year thereafter. Such negotiations shall take into
account, among other things, the competitive market conditions then existing, the cost of materials and labor, quantities of Products to be purchased by TLM and economic conditions. SOERING will apply best efforts to identify and implement cost
reduction strategies for the Products during the term of this Agreement and any/all extensions. 
  

 2 
 [*] =
Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. 

 2.3. Payment to SOERING for Products shall be made thirty (30) days following the date of the
invoice from SOERING (which shall be no earlier than the date of shipment) for Products specified in purchase orders and not rejected by TLM for nonconformance pursuant to Section 1, Paragraph 4.1. All payments to SOERING under this Agreement
shall be made in U.S. dollars. Both parties agree to share equally in any exchange rate fluctuation between the USD$ and Euro and will complete the following steps: 
  

	 	•	 	 At the outset of the arrangement, the parties will agree on a pre-defined exchange rate to be used during the first year of the Agreement. This rate will be the
average Euro/USD rate for the five days prior to the Effective Date as published in the New York edition of the Wall Street Journal. ($1.25/Euro 1.00) 

  

	 	•	 	 The pre-defined exchange rate will be reset on an annual basis to the exchange rate in effect on each anniversary of this Agreement as published in the Wall Street
Journal. 

  

	 	•	 	 At the end of each contract year, the parties will compare the average USD/Euro exchange rate during the year to the pre-defined exchange rate.

  

	 	•	 	 The resulting difference will be applied to the total of all invoices generated during the contract year and SOERING will either invoice or issue a credit memo to
TLM for 50% of the total. 

  

	 	3.	Shipment. 

 3.1. All sales of Products shall be F.O.B.
SOERING’s Quickborn factory at the prices set forth in Schedule B, which prices shall be exclusive of freight, insurance and taxes. SOERING shall, at TLM’s cost, ship the Products to any location chosen by TLM, utilizing carriers chosen by
TLM. Title and risk of loss or damage to the Products shall pass to TLM at the time they are loaded on to the carrier specified by TLM. 
 3.2. Unless otherwise agreed in advance, all Products, shall be packed, labeled, marked and otherwise prepared for shipment by SOERING in such a way as to be acceptable to carriers and in accordance with good commercial practice, so as to
minimize risk of loss or damage in transit. 
  

	 	4.	Specifications, Testing, and Warranty. 

 4.1. SOERING
agrees to sell the Products to TLM, for the term of this Agreement and warrants that such Products will meet the Specifications including modified specifications as may be agreed upon in writing by TLM and SOERING. SOERING shall include a
certification for any and all Products stating confirmation to the Specifications. 
 4.2. SOERING reserves the right to make engineering
changes that do not affect the form, fit, function, performance or appearance of the Products and that do not require regulatory approval without the prior approval of TLM; provided, however, that SOERING shall provide TLM with notice of such change
as promptly as practical before SOERING’s final internal approval of such change. With regard to all other material changes to the Products, SOERING agrees to give TLM written notice and to simultaneously provide TLM with Specifications for the
changes. No changes relating to the form, fit, function, performance or appearance will be made to any Products supplied to TLM at any time without the prior written approval or deemed approval as provided below of TLM. TLM agrees to inform SOERING
of its approval or disapproval of changes relating to the form, fit, function, performance or appearance of the Products within thirty (30) days after receiving notice of any such proposed changes. If TLM does not respond to SOERING within said
thirty (30)-day period, the change will be deemed to have been approved. 
  

 3 
 [*] =
Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. 

 4.3. TLM may request, in writing, that SOERING change the Specifications or otherwise incorporate changes
into the Products and/or develop customized Products for TLM. Such request will include a description of the proposed changes that will reasonably permit SOERING to evaluate the cost and feasibility. Within forty-five (45) days after receiving
such a request from TLM, SOERING will advise TLM whether it is reasonably able to make such changes and, if so, the timetable and terms and conditions under which it would make such changes, and any resulting increase or decrease in prices
hereunder. SOERING’s evaluation shall be in writing and, if it is reasonably able to make the change, it shall also state the impact on delivery schedules for Products covered by pending purchase orders hereunder. If, after good faith
negotiations, TLM and SOERING agree upon the terms of the changes, then this Agreement, the Specifications, delivery schedules (Schedule C) and pricing schedule (Schedule B) will be amended accordingly. 
 4.4. Within the times specified in this Paragraph 4.4, TLM shall have the right to return to SOERING, for full credit/refund plus cost of freight, any
Product that is defective or fails to comply with the Specifications, or any warranty provided with the Product to its end user as stated in the user manual and reproduced on Schedule D, provided, however, that such defect or failure is in no way
the result of any modification to the Product, improper repair, or of any damage (assuming proper packaging for transportation by SOERING) to the Product after loaded on to the carrier specified by TLM. Notwithstanding failure of TLM to inspect
and/or return any shipment, or its acceptance of any shipment, TLM shall be entitled to return to SOERING, for either repair, free of charge, credit/refund or exchange, at SOERING’s option, any Product that is defective or fails to comply with
the Specifications or any warranty provided with the Product to its end user as stated in the user manual and reproduced on Schedule D if returned to TLM within one (1) year after shipment of Generator Product by TLM to its end user or ninety
(90) days after shipment of any other Product by TLM to its end user. 
 4.5. In the event it is discovered by TLM, and SOERING is
notified by TLM within the time periods stated in Section I., Paragraph 4.4 hereof, that a Product is defective or fails to comply with the Specifications, or any warranty provided with the Product to its end user as stated in the user manual and
reproduced on Schedule D, TLM shall return the Product to SOERING and specify in writing the alleged complaint, Product code, serial number, if there is one, and the return address of TLM or the end user if the Product is to be drop shipped to the
end user. SOERING will, at its option and at its expense, either repair or replace such defective Product within fifteen (15) business days after its return by TLM, freight prepaid to SOERING at its repair facility, and receipt by SOERING at
such facility. If SOERING determines that the returned Product has been abused by the end user, SOERING shall provide TLM with a quote for repair of the Product and TLM shall either agree to pay for the repair, parts, labor and calibration or
instruct SOERING to return the Product to TLM without repairs. In either case, TLM shall pay the freight for return of the Product to TLM. SOERING shall charge TLM for any such repair, parts, labor and calibration as set forth in Section I,
Paragraph 4.6 hereof. 
 4.6. SOERING agrees to provide repair, maintenance, modification and other services on a timely basis on units of
the Generator Product purchased by TLM or its end user at $71.43/hour, plus the charges for repair parts. Notwithstanding the foregoing 

  

 4 
 [*] =
Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. 

 
sentence, the hourly rate that SOERING charges TLM for such services shall not exceed the lowest rate that SOERING charges any other customer for similar
services. Upon request by TLM, SOERING shall provide to TLM its then current price list for spare or replacement parts for Generator Products. SOERING agrees to maintain an adequate inventory of spare and replacement parts for the Generator Product
if and when production ceases for a period of at least five (5) years following the last delivery date of a Generator Product to TLM. 
  

	 	5.	Compliance With Laws and Regulations. 

 5.1. SOERING
represents and warrants that it is and, during the term of this Agreement, will continue to be (i) a Device Establishment, registered with the FDA and (ii) ISO 9001: 2000, ISO 13485: 2001 and ISO 13485: 2003 when certified on or before
April 30, 2006. SOERING further represents and warrants that all Products sold and delivered to TLM under this Agreement shall be manufactured in accordance with the Specifications, applicable industry standards and current Good Manufacturing
Practices (“cGMPs”) as set forth in the Quality System Regulation promulgated by the FDA and found in Code of Federal Regulations, Title 21 Part 820 (the “QSR”) and in accordance with all United States applicable statutes, laws,
standards and regulations (including, but not limited to, the United States Medical Devices Amendments of 1976) and the regulations promulgated thereunder, including the QSR, that are applicable to the Products. SOERING agrees to provide TLM with
copies of its FDA registration, Certification for ISO 9001: 2000 ISO 13485: 2001 and for ISO 13485: 2003 on or before April 30, 2006. 
 5.2. TLM, upon reasonable advance notice to SOERING during normal business hours, may on an annual basis visit SOERING manufacturing facilities to observe SOERING quality assurance procedures for testing, packaging and shipping during
SOERING’s initial production runs of the Products and shall have the right to audit SOERING’s manufacturing, documentation control, inspection and calibration systems. Such visits by TLM personnel will be mutually scheduled by TLM and
SOERING. 
 5.3. SOERING shall notify TLM of any FDA or TUV audit, or any audit from any other regulatory body, of its facilities for the
manufacture of the Products, or any request for information from the FDA or TUV or other regulatory body related to the manufacture of the Products, as soon as practicably possible after receipt of such notice of such audit or such request. SOERING
shall notify TLM as soon as practicable after receiving notice of any claim or action by the FDA or TUV or other regulatory body stating any non-compliance with this Paragraph 5 or any notice with respect to any violation of applicable statutes,
laws, rules or regulations. Both parties shall notify each other of any adverse reaction, malfunction, injury or other similar claims with respect to the Products or the devices in which they are incorporated, of which either party becomes aware.
The parties shall discuss and determine the responsibility for the investigation of all such complaints and the responsible party shall forward to the other a summary of its findings with respect thereto. TLM shall be responsible for managing all
customer and end-user communications with respect to such complaints and for filing any medical device report required to be filed with the FDA and vigilance reports required to be filed with 

  

 5 
 [*] =
Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. 

 
regulatory authorities in other jurisdictions in which the Products are marketed. Nothing herein shall preclude either party from taking any action that it
is required to take under applicable law or regulation. 
 5.4. Unless otherwise agreed to in writing by the Parties, TLM shall be
responsible for the preparation, submission and obtaining of appropriate documents for regulatory clearance to market the Products worldwide. SOERING shall provide TLM with such information as SOERING and TLM shall reasonably agree upon, for the
purpose of registration and/or regulatory clearance to sell the Products in any country in which TLM proposes to sell the Products. TLM shall be solely responsible, at its own cost, to obtain U.S. FDA clearance and the CE mark on any Products
subject to this Agreement. 
 5.5. If requested by TLM, SOERING, at TLM’s cost, shall take all steps necessary to obtain and maintain
determinations that the Products meet the consensus-based standards of safety required by the Occupational Safety and Health Act as determined by one or more Nationally Recognized Testing Laboratories and the equivalent approvals under the
applicable standards promulgated by the Canadian Standards Association, the International Electrotechnical Commission, the German Technical Inspection Associations (TUVs) or their equivalents in other jurisdictions. 
 5.6. This Agreement shall be reviewed by SOERING at least annually for compliance to ISO 9001: 2000 and ISO 13485: 2001 and for ISO 13485: 2003 when
certified on or before April 30, 2006. 
 5.7. Unless otherwise agreed to in writing by the parties, SOERING shall take all action
necessary and bear all engineering costs incurred to insure that the Products and any changes or improvements to the Products conform with applicable regulatory standards required to allow application of the CE mark for the Products, recognizing
that TLM will be responsible for obtaining the CE mark for the Products and all costs for submission and testing in connection associated therewith. 
  

	 	6.	Product Recall. 

 If either party believes that because of
a defect in manufacturing or design a recall, market withdrawal, safety alert or similar action (“Recall”) of any Products is desirable or required by law, it will promptly notify the other party. The parties will then discuss reasonably
and in good faith whether such Recall is appropriate or required and the manner in which the Recall shall be handled. The decision on the appropriate recall action is the sole responsibility of TLM. This Paragraph 6 shall not limit the obligations
of either party under law with respect to Recall of Products required by law or properly mandated by governmental authority. SOERING shall bear all reasonable costs and expenses of any such Recall, which relates to the manufacture or design of the
Products. TLM shall maintain complete and accurate records for such periods as may be required by applicable law of all the Products sold by it. The parties will cooperate fully with each other in effecting any Recall of the Products pursuant to
this Paragraph 6. However, TLM shall be responsible for the actual conduct of any Recall of the Products, including communications with customers and end-users, and for any required notification to the FDA and other applicable regulatory authorities
in respect thereof. SOERING agrees to comply with TLM product complaint reporting system and to provide all necessary data to complete investigations. 
  

 6 
 [*] =
Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. 

	 	7.	Product Name/Private Labeling. 

 TLM shall have the right
to market and advertise Products exclusively under TLM’s name, trademarks, trade names, labels or other designations (collectively referred to as the “Marks”) for the term of this Agreement. All of such Marks shall remain the property
of TLM, and SOERING shall have no rights thereto. TLM agrees to recognize the role of SOERING as manufacturer of the Products through identification of SOERING on the Products and literature relating thereto with the “Manufactured by
SOERING.” logo, except as otherwise required for CE marked Products. 
  

	 	8.	Patent Infringement. 

 8.1. SOERING represents that the
waveform and circuitry of the Generator Product is exclusively owned or licensed by SOERING. SOERING shall not knowingly employ in the performance of this Agreement, or include in any Product, including Generator Product, which SOERING supplies
hereunder to TLM, any technology exclusively licensed by SOERING to a third party, or in which is owed by a third party from whom SOERING has not obtained a license to use such technology, other than standard, commercially available technology for
which no license or payment is required to make, use, sell, distribute or otherwise utilize such technology. If a third party claims that the sale, distribution or use of any Product infringes a patent or trademark owned by that third party and such
party threatens to commence or commences a suit or action based upon such claim, the parties agree to notify each other promptly of such threat of action or action, and to cooperate with each other in the defense of such a suit or action, subject to
the indemnification obligations set forth in Section II., Paragraph 4.1. 
 8.2. If the sale, distribution or use of any Product
including Generator Product, which SOERING supplies hereunder to TLM infringes on the patent of a third party, and TLM or its customer is enjoined by final judgment of a court of competent jurisdiction from using the Product, SOERING shall (or if
any Product or part thereof becomes, or in SOERING’s opinion is likely to become, the subject of a claim of infringement of any intellectual property right of a third party, SOERING may), at SOERING’s option, either (i) replace or
modify the Product so that it becomes non-infringing or (ii) procure for TLM the right to continue to sell the Product for the term of this Agreement, or, if neither (i) or (ii) is feasible, terminate this Agreement with regard to the
infringing Product and repurchase all TLM’s inventory of the infringing Product at the price paid by TLM, including freight. 
  

	 	9.	Manufacturing Rights. 

 9.1. (a) Should SOERING be unable
to or fail for any reason, other than as set forth in Section 1, Paragraph 9.2 hereof, to manufacture a Product in quantities at least equal to the Initial Products Minimum or the applicable Forecast, as the case may be, that are in accordance
with the agreed upon Specifications, applicable industry standards and current Good Manufacturing Practices (“cGMPs”) as set forth in the Quality System Regulation promulgated by the FDA and found in Code of Federal Regulations, Title 21
Part 820 (the “QSR”) that are applicable to the Products (hereinafter referred to as a “Manufacturing Deficiency”), TLM within 30 

  

 7 
 [*] =
Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. 

 
days of the discovery of the Manufacturing Deficiency, on one hundred and twenty (120) days prior written notice to SOERING, may: (i) remove the
particular Product from the terms of this Agreement; or (ii) exercise the right to designate a manufacturer, set forth in Paragraph 9.1(b) herein. During the one hundred and twenty (120)-day notice period set forth in the preceding
sentence, SOERING will have the right to cure such Manufacturing Deficiency in order to keep the particular Product in compliance with the terms of this Agreement and, if it is successful in doing so, the notice shall be null and void. 

(b) In the event that SOERING fails to cure the Manufacturing Deficiency, TLM may at TLM’s option find and contract with another source within
thirty (30) days to manufacture the Product in accordance with the Specification. SOERING agrees to provide such source with the technology, know how and documentation necessary to enable it to manufacture the Product and to render such other
assistance as may reasonably be requested to assure an orderly transition of the manufacturing operation and assign any applicable patent license. 
 9.2. SOERING shall not be liable for any failure to supply or deliver, or for any delay in the delivery of, the Products hereunder, when any such failure or delay is caused, directly or indirectly, by fires, floods, accidents, explosions,
strikes or other labor disturbances (regardless of the reasonableness of the demands or labor), wars, shortages of fuel, power or raw materials, inability to obtain or delays of transportation facilities, acts of God, or any cause, whether similar
or dissimilar, to the foregoing beyond the reasonable control of SOERING (a “Force Majeure Event”), as the case may be, affecting SOERING’s production and/or delivery of the Products covered by this Agreement or TLM’s acceptance
or resale thereof. Such failure will be excused for three months or as long as such event shall be continuing (whichever period is shorter) provided that SOERING gives immediate written notice to TLM of the Force Majeure Event. SOERING shall
exercise all reasonable efforts to eliminate the Force Majeure event and to resume performance. In the event the failure continues beyond three months, then TLM may at TLM’s option find and contract with another source within thirty
(30) days from the end of the three-month period to manufacture and supply the Products. SOERING agrees to provide such source with the technology know how and documentation necessary to enable it to manufacture the Products and to render such
other assistance as may reasonably be requested to assure an orderly transition of the manufacturing operation and assign any applicable patent license. SOERING agrees to maintain sufficient records and documentation in a secure place other than the
place of manufacture to insure the ability to cure and/or transfer. 
 9.3. Should TLM terminate this agreement TLM shall be obligated to
purchase all related finished goods, work in process, and parts which Soering possesses or has ordered at that time which quantities shall not exceed the then current 12 month forecast. 
 SECTION II. GENERAL PROVISIONS 
  

	 	1.	Term. 

 1.1. Unless terminated sooner pursuant to Section
II., Paragraph 2 hereof or extended as provided herein, the term of this Agreement shall commence on the Effective Date and shall continue in force until the end of the third Agreement Year. If on or before the end of the third Agreement Year, the
term of this Agreement has not been extended for additional 3 years beyond the end of the third Agreement Year by written agreement of TLM and SOERING, the parties on written notice from either party shall for a 

  

 8 
 [*] =
Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. 

 
period of ninety (90) days after such written notice (but in no event shall such period extend past the end of the third Agreement Year) conduct good
faith discussions at mutually convenient times regarding the terms and conditions of an extension to this Agreement. 
  

	 	2.	Termination and Remedies. 

 2.1. Either party may terminate
this Agreement upon written notice to the other party in the event of a material breach of this Agreement by the other party which is not cured within ninety (90) days after written notice of such breach is given. Notwithstanding the foregoing,
(i) in the event TLM fails to timely pay for shipped Products within the time period set forth in Section I, Paragraph 2.3 or breaches the covenants and agreements in Section I, Paragraph 8.2 (a), SOERING may terminate the Agreement if such
breach is not cured within ten (10) days after written notice by SOERING: (ii) in the event of a breach of Section II, Paragraph 3, and in addition to all other rights and remedies that SOERING has under this Agreement or at law or equity,
SOERING may terminate this Agreement within ten (10) days after written notice to TLM. 
 2.2. Either party, at its election, may
declare the other party to be in default under the Agreement and, without prejudice to any of its rights hereunder, may forthwith terminate the Agreement by written notice to the other party in the event the other party (i) makes a general
assignment for the benefit of creditors, (ii) has a receiver of all or substantially all of its assets appointed, (iii) files a voluntary petition for reorganization or other arrangement or in bankruptcy under the U.S. bankruptcy laws, the
equivalent German bankruptcy laws or (iv) is declared insolvent. 
 2.3. Notwithstanding anything to the contrary in this Agreement, any
termination of this Agreement will not affect any rights of either party arising under this Agreement prior to such termination. In addition each party shall have all rights and remedies available to it at law or equity, except as limited by the
terms of, Section II, Paragraph 2.4, below. 
 2.4. NOTWITHSTANDING ANYTHING IN THIS AGREEMENT TO THE CONTRARY, EACH PARTY HERETO WAIVES ANY
CLAIM TO PUNITIVE DAMAGE OR EXEMPLARY DAMAGES FROM THE OTHER. NOTWITHSTANDING ANYTHING IN THIS AGREEMENT TO THE CONTRARY, EACH PARTY HERETO WAIVES ANY CLAIM OF CONSEQUENTIAL DAMAGES FROM THE OTHER EXCEPT WITH RESPECT TO ANY BREACH OF SECTION II,
PARAGRAPH 3; IT BEING AGREED THAT A PARTY MUST PROVE THE EXISTENCE OF, AND ITS ENTITLEMENT TO, CONSEQUENTIAL DAMAGES WITH RESPECT TO A BREACH OF SECTION II, PARAGRAPH 3 IN ACCORDANCE WITH APPLICABLE LAW. 
  

	 	3.	Confidential Information. 

 3.1. As used herein,
“Confidential Information” shall mean the Specifications, all know-how relating to the development, manufacture, sale or use of any Product, including, without limitation, processes, techniques, methods, products, apparatuses, and
materials and compositions which are reasonably related thereto, the direct labor, direct overhead and raw materials costs incurred in 

  

 9 
 [*] =
Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. 

 
the manufacture of Product, the raw material, and all other confidential or proprietary information that is reduced to writing, marked as confidential and
given to one party by the other party relating to such other party or any of its affiliates, including information regarding any of the Products of such other party or any of its affiliates, information regarding its advertising, distribution,
marketing or strategic plans or information regarding its costs, productivity or technological advances. Neither party shall, during the term of this Agreement and for a period of five (5) years following the termination or expiration of this
Agreement for any reason, use or disclose to third parties any Confidential Information of the other (except to the extent reasonably necessary to exercise its rights or comply with its obligations under this Agreement) and each party shall insure
that its employees, officers and agents shall not use or disclose to third parties any Confidential Information of the other (except to the extent reasonably necessary to exercise its rights or comply with its obligations under this Agreement);
provided, however, that TLM and SOERING may disclose Confidential Information to their employees on a need to know basis provided such persons are informed of the confidential nature of such information and are under contractual obligation to not
use the Confidential Information and to keep such information confidential. Confidential Information shall not include information that (i) was already known to the receiving party at the time of its receipt thereof, as evidenced by its written
records, (ii) is disclosed to the receiving party after its receipt thereof by a third party who has a right to make such disclosure without violating any obligation of confidentiality, (iii) is or becomes part of the public domain through
no fault of the receiving party or (iv) is required to be disclosed to comply with applicable laws or regulations or an order of a court or regulatory body having competent jurisdiction. 
 3.2. In the event that a party receives a subpoena which requires the disclosure of Confidential Information, such party shall provide the other party at
least ten (10) days’ written notice of such subpoena prior to the return date, or as much advance notice as possible if the return date is in less than ten (10) days, to allow the other party to move to quash such subpoena. The party
shall not disclose the Confidential Information during the notice period and during the pendency of any motion to quash the subpoena. 
 3.3.
Title to all tangible forms of Confidential Information, including any copies thereof, shall be and remain with discloser. The recipient shall not copy or reproduce, in whole or in part, any Confidential Information from the discloser without
written authorization except as is necessary to fulfill the purpose of this Agreement. Upon written request or termination of this Agreement, all tangible forms of Confidential Information with exception of an archive copy to be used solely for
compliance with the recipient’s obligations under this Agreement or applicable law, shall be promptly returned to the discloser or destroyed. 
  

	 	4.	Indemnification and Insurance. 

 4.1. SOERING shall
indemnify and hold TLM harmless against any and all claims, suits, proceedings, expenses, attorney’s fees, recoveries and damages, including expenses of total or partial Recall of Products, caused by defects in design, materials, or workmanship
of the Products or based on a claim that the Products or their use infringes upon the claim of a patent of a third party (except to the extent that infringement arises in a Generator Product exclusively from the relationship of power level and fluid
rate of TLM). The indemnification obligation, however, shall not apply if any Product is used in conjunction with a device, instrument or 

  

 10 
 [*] =
Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. 

 
product that is not approved for use with the Product. SOERING has and shall maintain product liability insurance in the amount of 7.5 million Euros for
the duration of this Agreement. 
 4.2. TLM shall indemnify and hold SOERING harmless against any and all claims, suits, proceedings,
expenses, recoveries and damages, including expenses of total or partial Recall of Products caused by TLM’s distribution practices or TLM’s advertising or promotional material for the Products, misrepresentations by TLM, use of the Product
in an application or an environment for which it was not designed or contemplated hereunder, or modifications to, or improper repair of the Product or damage to the Products caused by unauthorized repair or modification of the Products by TLM. TLM
has and shall maintain product liability insurance in the amount of $1,000,000 for the duration of this Agreement. 
  

	 	5.	No Transfer of Patent and Know-How. 

 Nothing in this
Agreement constitutes or shall be construed as a transfer to either party of any of the patents, intellectual property rights, trade secrets or know-how relating to the Products or any other products or products-in-development of or a license for
either party to use such patents, intellectual property rights, trade secrets or know-how. 
  

	 	6.	Representations, Warranties and Agreements of SOERING. 

 6.1. SOERING is a corporation duly organized and validly existing in good standing under the laws of Germany. SOERING has the corporate power to execute, deliver and perform this Agreement. 
 6.2. The execution and delivery of this Agreement by SOERING does not, and the performance of SOERING’s obligations hereunder will not, violate any
provision of the organization documents of SOERING or violate any provision of, or result in a breach of any of the terms or provisions of or the acceleration of any of the obligations under, or constitute a default under, any mortgage, lease,
agreement, instrument, order, arbitration award, judgment or decree to which SOERING is a party or to which SOERING or its assets, properties or business are subject to on the date hereof. This Agreement is a valid and binding agreement of SOERING
enforceable against it in accordance with its terms. 
 6.3. SOERING is not party to any agreement with or obligation to any third-party or
any other legally binding commitment of any kind or nature whatsoever that would, in the reasonable opinion of SOERING, adversely affect SOERING’S ability to perform the terms of this Agreement. 
 6.4. No approval of any person, entity or government authority is necessary with respect to the execution, delivery and performance by SOERING of this
Agreement. 
  

	 	7.	Representations, Warranties and Agreements of TLM. 

 7.1.
TLM is a corporation duly organized and validly existing in good standing under the laws of Delaware. TLM has the corporate power to execute, deliver and perform this Agreement. 
  

 11 
 [*] =
Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. 

 7.2. The execution and delivery of this Agreement by TLM does not, and the performance of TLM obligations
hereunder will not, violate any provision of the organization documents of TLM or violate any provision of, or result in a breach of any of the terms or provisions of or the acceleration of any of the obligations under, or constitute a default
under, any mortgage, lease, agreement, instrument, order, arbitration award, judgment or decree to which TLM is a party or to which TLM or its assets, properties or business are subject to on the date hereof. This Agreement is a valid and binding
agreement of TLM enforceable against it in accordance with its terms. 
 7.3. TLM is not party to any agreement with or obligation to any
third-party or any other legally binding commitment of any kind or nature whatsoever that would, in the reasonable opinion of TLM, adversely affect TLM’s ability to perform the terms of this Agreement. 
 7.4. No approval of any person, entity or government authority is necessary with respect to the execution, delivery and performance by TLM of this
Agreement. 
  

	 	8.	Miscellaneous. 

 8.1. This Agreement is not intended to
create a partnership, association, joint venture or unincorporated business between SOERING and TLM, or any other type of entity which could be determined to be obligated to file tax or reporting returns pursuant to the Internal Revenue Code (or
similar taxing laws of any county or U.S. State). Except as otherwise provided herein, each party hereto shall be responsible for the payment of all expenses or obligations incurred by it, including payments of withholding, social security, or other
taxes or charges applicable to its employees, consultants, or contractors. Except as provided herein, neither party shall have the right to make any agreement in the name of the other party, nor obligate the other party to pay any amount, perform
any act, or incur any liability or obligation. 
 8.2. Except as specifically agreed to in writing, each party shall bear all cost and
expenses, which it incurs in connection with this Agreement. 
 8.3. Except as provided below, this Agreement may only be assigned with the
prior written consent of the other party, which consent shall no be unreasonably withheld notwithstanding the foregoing, (i) a business combination transaction that results in another person or entity becoming the owner of in excess of 35% of
either parties voting shares, (new company) whether through merger or sale of stock or acquiring all or substantially all of the assets of either party, or otherwise obtaining effective operating control of either party or (ii) any other change
in either parties stockholders shall not constitute an assignment of this Agreement by either party that requires the other parties consent provided that either party obtains the written Agreement of any new company to be bound by this Agreement as
were the parties. In the event of any permitted assignment pursuant to this paragraph 8.3, the assignee including without limitation a new company (The “Permitted Assignee” ) shall automatically be entitled to the benefits and terms of
this Agreement as was the assignor from and after the date of such assignment and shall automatically be obligated as was the assignor as to all obligations then accrued or thereafter to accrual under this Agreement. 
  

 12 
 [*] =
Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. 

 8.4. No amendment of modification or addition hereto shall be effective or binding on either of the
parties hereto unless or until the same is reduced to writing and signed by both parties. 
 8.5. This Agreement, together with its Schedules
A, B, C, D and Exhibit (currently no exhibit), embodies the entire understanding between the parties regarding the subject matter hereof and supersede any and all prior understandings and agreements relating to such subject matter. 
 8.6. The validity and interpretation of this Agreement shall be governed by the laws of the State of New Hampshire. 
 8.7. If the performance of this Agreement or any obligation hereunder, except the making of payments hereunder, is prevented, restricted or interfered
with by reason of fire, flood, earthquake, explosion or other casualty or accident; strikes or labor disputes; inability to procure parts, supplies or power, war or other violence; any law, order, proclamation, regulation, ordinance, demand or
requirement of any government agency; or any other act or condition whatsoever beyond the reasonable control of the affected party, the party so affected, upon giving prompt notice to the other party, shall be excused from such performance to the
extent of such prevention, restriction or interference; provided, however, such prevention, restriction or interference does not continue for more than one hundred and twenty (120) days and provided that the party so affected shall take all
reasonable steps to avoid or remove such causes of nonperformance and shall resume performance hereunder with dispatch whenever such causes are removed prior to such one hundred and twenty (120) days. This Paragraph 8.8 shall not be applicable
to the failure of SOERING to supply or deliver, or for any delay in the delivery of, the Products, which failure or delay shall be covered by Section I, Paragraph 9.2. 
 8.8. It is expressly understood that the failure of either party to enforce any rights arising from the failure of the other party to perform, or perform properly, the other party’s obligations hereunder shall
not constitute a waiver of its rights arising from such failure or improper performance, and that enforcement of any right hereunder shall not preclude exercise of any other remedies available at law. All rights and remedies, whether conferred
hereby or by any other instrument or by law shall be cumulative, and may be exercised singularly or concurrently. 
 8.9. If any provision of
the Agreement is held invalid by law, rule, order, or regulation of any government or by the final determination of any court of the United States, such invalidity shall not affect the enforceability of any other provision in this Agreement not held
to be invalid. 
 8.10. This Agreement may be signed in counterparts; each counterpart shall constitute an original document, but all of
which shall constitute one instrument. This Agreement may be duly executed and delivered by a party by execution and facsimile delivery of signature page of a counterpart to the other party, provided that, in such case, the executing party shall
promptly deliver a complete counterpart that it has executed to the other party. 
  

 13 
 [*] =
Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. 

 8.11. Any press release or other disclosure to the public regarding this Agreement and the transactions
contemplated hereby shall be mutually agreed upon by the parties hereto; provided, however, that either party may make any such public announcement or disclosure that counsel advises in writing is required by applicable securities laws or
regulations or rules or agreements with any stock exchange on which its shares are listed, in which case the party making the announcement or disclosure shall inform the other party in advance of the timing and proposed content and shall provide the
other party with reasonable opportunity to review and comment on any such required announcement or disclosure. 
 8.12. All notices and
consents hereunder shall be in writing and shalt be deemed to have been properly given and to be effective on the date of delivery if delivered in person, by one-day courier service or by facsimile transmission (provided a copy is sent by one-day
courier service) to the respective address or facsimile number provided below or to such other address or facsimile number as either party shall designate by written notice to the other in such manner: 
 To TLM: 
 TissueLink Medical, Inc. 
 One Washington Center, Suite 400 
 Dover, New Hampshire 03820 
 Attention: M. Jacqueline Eastwood, President & CEO 
 Facsimile: (603) 749-5024

 with a copy to: 
 Steve Wilcox, Esq. 
 Ropes & Gray 
 One International Place 
 Boston, MA 02110 
 Facsimile: (617) 951-7050 
 To SOERING: 
 Soering, GmbH 
 Justus-von-Liebig-Ring 2, D-25451, 
 Quickborn, Germany 
 Attn: Holger Soring, President 
  

 14 
 [*] =
Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. 

 IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed as of the Effective Date
by their duly authorized officers. 
  

									
	TissueLink Medical, Inc.	 		 	SOERING GmbH
					
	By:	 	/s/ M. Jacqueline Eastwood	 		 	By:	 	/s/ Holger Soring
	Name:	 	M. Jacqueline Eastwood	 		 	Name:	 	Holger Soring
	Title:	 	President	 		 	Title:	 	President
	Date:	 		 		 	Date:	 	

  

 15 
 [*] =
Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. 

 SCHEDULE A “PRODUCTS” 
 Article No. 

			
	TL200-0000	  	Aquamantys Unit * includes tray, power cable, user guide, service manual (the “Generator Product”)
		
	xxxxxxxxx	  	Packaging
		
	Parts:	  	
	Article#	  	
	Art #	  	Name
	200N0012	  	Power Cable for US and Canada
	200N0023	  	Power Cable for Europe
	700N0034	  	Pump head, 3-roller
	740S0042	  	Case
	300K0050	  	Motor unit (incl. Pre assembled)
	800S0013	  	Transformer
	810K1220	  	Panel Board
	810K1240	  	Main Board, pre adjusted
	810K1250	  	Mains Board
	300K0051	  	Heat Sink & Fan (pre assembled)
	800N0076	  	Mains Filter
	820K0040	  	Bipo Socket
	750S0500	  	Upper Front Label
	750S0501	  	Lower Front Label

  

	*	Inspection Sample received July 13, 2005. Modified board with priming timing change expected week of Aug 22, 2005. 

  

 16 
 [*] =
Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. 

 SCHEDULE B 
 Unit price of Aquamantys is based on 12 month forecasted volume. The first 12 month forecast is attached as Schedule C and future 12 month forecasts will be established according to paragraph 2.2. Prices are firm to
the 12 month forecasted volume. No credit adjustment will be made if volume exceeds the 12 month forecast. 
  

									
	 Annual amount
	  	Single
Device costs	  	Sum	  	Discount
	100	  	$	[*]	  	$	[*]	  	[*]%
	200	  	$	[*]	  	$	[*]	  	[*]%
	250	  	$	[*]	  	$	[*]	  	[*]%
	300	  	$	[*]	  	$	[*]	  	[*]%

 Parts Pricing : no quantity discount 
  

					
	 Art#
	  	 Name
	  	VK
	200N0012	  	Power Cable for US and Canada	  	$[*]
	200N0023	  	Power Cable for Europe	  	$[*]
	700N0034	  	Pump head, 3-roller	  	$[*]
	740S0042	  	Case	  	$[*]
	300K0050	  	Motor unit (incl. Pre assembled)	  	$[*]
	800S0013	  	Transformer	  	$[*]
	810K1220	  	Panel Board	  	$[*]
	810K1240	  	Main Board, pre adjusted	  	$[*]
	810K1250	  	Mains Board	  	$[*]
	300K0051	  	Heat Sink & Fan (pre assembled)	  	$[*]
	800N0076	  	Mains Filter	  	$[*]
	820K0040	  	Bipo Socket	  	$[*]
	750S0500	  	Upper Front Label	  	$[*]
	750S0501	  	Lower Front Label	  	$[*]
		  	 Sum
	  	$[*]

 Shipping: 
 Time: 2-4
weeks after receipt of order within 115% of forecast. Amounts over 115% to be shipped in 8 weeks or less. 
 Term of Delivery: EX Works Quickborn/Germany

 Mode of Delivery: Specified by TLM. 
 Packaging Cost: $[*] per
Aquamantys Unit 
  

 17 
 [*] =
Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. 

 SCHEDULE C 
 Initial Products Minimum for: 
 Article No. TL200-0000 Aquamantys (incl. Tray) and Power 
 Cable Article No. 200N0012 
  

			
	 Month
	  	# Delivered
	 Oct 2005
	  	10
	 Nov 2005
	  	20
	 Dec 2005
	  	20
	 Jan 2006
	  	25
	 Feb 2006
	  	25
	 Mar 2006
	  	25
	 Apr 2006
	  	12
	 May 2006
	  	12
	 Jun 2006
	  	11
	 Jul 2006
	  	12
	 Aug 2006
	  	12
	 Sep 2006
	  	11
	 Oct 2006
	  	12
	 Nov 2006
	  	12
	 Dec 2006
	  	11

  

 18 
 [*] =
Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. 

 SCHEDULE D 
 Pump Generator and Cart Warranty 
 (to be provided in the user’s manual and the service manual): 
 LIMITED EXPRESS WARRANTY 
 For one (1) year from
the date of shipment from TissueLink, if an Aquamantys Pump Generator or Cart is found, to TissueLink’s satisfaction, to be inoperable during normal and proper use in accordance with applicable instructions, TissueLink Medical, Inc. will repair
or replace the product, at its sole option, provided the product is returned, freight prepaid, in accordance with all return packaging and shipping instructions. A product repaired or replaced under this warranty will be warranted for the remainder
of the original warranty period. 
 TISSUELINK MEDICAL, INC. MAKES NO OTHER WARRANTIES WITH RESPECT TO THE PRODUCT AND EXPRESSLY DISCLAIMS ALL OTHER
WARRANTIES, EXPRESS OR IMPLIED, AS TO MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE OR ANY OTHER MATTER. IN NO EVENT SHALL TISSUELINK MEDICAL, INC. BE LIABLE FOR ANY CONSEQUENTIAL DAMAGES. 
 THE ABOVE WARRANTY IS VOID ON ANY PRODUCT WHICH HAS BEEN MODIFIED OR REPAIRED OTHER THAN BY TISSUELINK OR AN AUTHORIZED REPRESENTATIVE, IMPROPERLY INSTALLED, USED,
MAINTAINED OR STORED, OR SUBJECT TO ABUSE, MISUSE, NEGLECT OR ACCIDENT. TISSUELINK IS NOT RESPONSIBLE FOR DAMAGE OR ANY OTHER LOSS DURING RETURN SHIPMENT. 
  

 19 
 [*] =
Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. 

 SCHEDULE D 
 Warranty On Repairs and Replacement Parts 
 (to be provided with repair quote in the future): 
 After the original warranty has expired, repairs and replacement parts are warranted for ninety (90) days from the date of shipment. This warranty extends only to
those items repaired or replaced by TissueLink or an authorized representative, and does not extend to any other items. 
  

 20 
 [*] =
Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. 

					
		 		 	One Washington Center
Suite 400
	TISSUELINK TM	 		 	Dover. NH 03820
	Simply Better Surgery	 		 	Phone 603-742-1515
		 		 	Far 603-742403

 Supply and Distribution Agreement 
 Schedule B and C Updates 
 The following schedules are the January 2008 updates to the Supply
and Distribution agreement between TissueLink Medical, Inc and Soering, GmbH as set forth in section 2.2 of the original agreement dated September 15, 2005. 
 This agreement is effective for the dates of January 1, 2008 through December 31, 2008 at which time all other schedule B and Schedule C agreements are no longer in effect. The payment terms and exchange rate listed below will be
in effect from January 1, 2008 through December 31, 2008 and supersede those listed in earlier agreements. 
 Schedule B 
 The 2008 unit price for the Aquamantys is based on a 12 month forecasted volume as discussed in Schedule C. Prices are firm for the length of this agreement. The
forecasted volume will be reviewed at the end of the year and the unit price may be adjusted per the price schedule listed below for the equivalent annualized rate. No credit adjustment will be made if volume exceeds the forecast amount within the
first six months or in the second six months. The Aquamantys pricing listed below applies to all current models regardless of the configuration required for individual countries or destinations. 
 Basic Unit Cost* [*] Euros 
  

	*	includes new exchange rate ([*]), precious metal motor increase (plus [*] euros ea). 

  

											
	 Annualized Qtv
	  	Discount	  	Price
Each
(Euros)	  	Price Each
115V
(US Dollars)	  	Price Each
230V**
(US Dollars)
	 Up to 249
	  	[*]%	  	[*]	  	$	[*]	  	$	[*]
	 Up to 499
	  	[*]%	  	[*]	  	$	[*]	  	$	[*]
	 Up to 749
	  	[*]%	  	[*]	  	$	[*]	  	$	[*]
	 Over 749
	  	[*]%	  	[*]	  	$	[*]	  	$	[*]

  

	**	230V Generic unit cost also includes longer power cords (plus $[*] each). 

 Parts Pricing: No Quantity Discount 
  

						
	 Art #
	  	 Name
	  	Price Each
(US Dollars)
	200N0006	  	Power Cable for UK	  	$	[*]
	200N0012	  	Power Cable for US and Canada	  	$	[*]
	200N0023	  	Power Cable for Europe	  	$	[*]
	200N0031	  	Power Cable for Europe 4.5m	  	$	[*]
	200N0032	  	Power Cable for UK 4.5m	  	$	[*]
	700N0034	  	Pump Head, 3 Roller	  	$	[*]
	740S0042	  	Case	  	$	[*]
	740K0072	  	Precious Metal Motor	  	$	[*]
	800S0013	  	Transformer	  	$	[*]
	810K1220	  	Panel Board	  	$	[*]
	810K1240	  	Main Board, Pre Adjusted	  	$	[*]
	810K1250	  	Mains Board	  	$	[*]
	3001K0051	  	Heat Sink & Fan (Pre Assembled)	  	$	[*]
	800N0076	  	Mains Filter	  	$	[*]

  

 Page 1 of 2 
 [*] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. 

 Parts Pricing: No Quantity Discount 
  

						
	 Art #
	  	 Name
	  	Price Each
(US Dollars)
	820K0040	  	Bipo Socket	  	$	[*]
	750S0500	  	Upper Front Label	  	$	[*]
	750S0501	  	Lower Front Label	  	$	[*]
	750S0505	  	Pump Head Logo	  	$	[*]
	750S0506	  	Warning Sticker	  	$	[*]
	200N0060	  	Main Switch	  	$	[*]
	200N0063	  	Cap for Main Switch	  	$	[*]
	03-000X	  	User Guides (EN, DE or 1T)	  	$	[*]
	03-0004	  	service Manual (EN)	  	$	[*]
	0	  	Software Flash	  	$	[*]
	0	  	Exchange of Main Boards	  	$	[*]
	01-000	  	Technician Working hour	  	$	[*]
	01-002	  	Engineer Working Hour	  	$	[*]
	01-101	  	PSC (Safety Check)	  	$	[*]

  

 [*] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of
this exhibit has been filed separately with the Commission. 

 Terms 
 Shipment 2-4
weeks after receipt of order for quantities within 115% of forecast, Amounts over 115% are to be shipped in 8 weeks or less. 
 Term of Delivery: EX Works
Quickbom / Germany 
 Mode of Delivery: Specified by TissueLink Medical 
 Packaging Cost: $[*] per Aquamantys unit 
 Cert Cost: $[*] per Aquarnantys unit 
 Terms of Payment: 15 days from date of invoice 
 Exchange Rate: [*] Euro: Dollar 
 Exchange rate fluctuations are to be monitored by TissueLink Medical and Soring GmbH. If the fluctuations in the exchange rate are excessive, then either party may
release an invoice for the recovery of exchange rate expenses prior to December 31, 2008. Payment of and/or release of an invoice must be agreed upon by both parties. 
 Schedule C 
 Every month a rolling 12 month forecast for the Aquamantys units (Article TL200-0000 including Reference
Tray Label, User Guides, Service Manuals and Power Cable) will be provided to Soring GmbH by TissueLink Medical. The quantities given are subject to change per section 1.3 of the agreement and are provided for forecasting and planning purposes.

 IN WITNESS WHEREOF, the parties hereto have caused this revision to this agreement to be executed as of the Effective Date by their duly authorized
officers. 
  

									
	Tissuelink Medical, Inc.	 		 	Soring GmbH
					
	By:	 	/s/ Tad Vaughn	 		 	By:	 	/s/ Holder Soring
	Date:	 	1-22-08	 		 	Date	 	7-01-2008
		 	Tad Vaughn	 		 		 	Holger Sorino
	Title:	 	VP of Operations	 		 	Title:	 	President

  

 [*] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of
this exhibit has been filed separately with the Commission.Contract Manufacturing General Agreement between the Registrant and Design Stand

 Exhibit 10.19 
 CONTRACT MANUFACTURING GENERAL AGREEMENT 
 This Manufacturing Agreement (the
“Agreement”) is entered into as of this 10th day of November, 2004, by and between TissueLink Medical, Inc., a Delaware corporation, having its principal place of business at 1 Washington Center, Suite 400, Dover, NH 03820
(the “Customer”), and Design Standards Corporation, a Connecticut corporation, having its principal place of business at CEDA Industrial Park, P.O. Box 1620, Charlestown, NH 03603 (the “Manufacturer”). 

WHEREAS, Customer wishes to contract the manufacture of its medical devices (described in attached Device Specific Schedule(s), hereafter referred to
as the “Products”); and 
 WHEREAS, Manufacturer is engaged in the business of manufacturing medical devices, 
 NOW THEREFORE, the parties agree as follows: 
  

	1.	Representations of Customer and Manufacturer 

  

	1.1	Customer represents to Manufacturer that: 

  

	 	a.	This Agreement has been duly authorized. 

  

	 	b.	The execution and delivery by Customer of this Agreement, and the performance by the Customer of its obligations hereunder do not and will not infringe or constitute a breach of the
charter or the by-laws of Customer or any other agreement to which it is a party. 

  

	 	c.	The manufacture of the Products in accordance with the Product Specifications, as described in attached Device Specific Schedule(s), to the knowledge of Customer, do not and will
not infringe intellectual property rights of any third party. 

  

	1.2	Manufacturer represents to Customer that: 

 This Agreement
has been duly authorized. 
  

	 	a.	The execution and delivery of this Agreement by Manufacturer and the performance by Manufacturer of its obligations hereunder do not and will not infringe or constitute a breach of
the charter or the by-laws of Manufacturer or any other agreement to which Manufacturer is a party. 

  

	2.	Scope of the Agreement 

  

	2.1	Manufacturer will manufacture the Product in accordance with (i) the Product Specifications as described in attached Device Specific Schedule(s); (ii) Good Manufacturing
Practices (as defined in Section 7.1) and Quality Systems (as defined in Section 7.6); (iii) pertinent rules and regulations of the Food and Drug Administration (the “FDA”); and (iv) applicable international standards,
including CE (European Community) mark standards for medical devices. Upon the request of Customer, Manufacturer shall provide Customer with written evidence of compliance with the criteria set forth in the preceding sentence.

  

 [*] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of
this exhibit has been filed separately with the Commission. 

	3.	Intellectual Property 

  

	3.1	Customer Ownership. Customer shall exclusively own all right, title and interest in and to, and all patents, copyrights, trademarks, mask works, trade secrets and other
intellectual property rights (the “Intellectual Property Rights”) related to: 

  

	 	a.	the Products; 

  

	 	b.	all manufacturing processes, know-how and other information and materials provided by Customer to Manufacturer before and after the Effective Date of this Agreement (the
“Information”), including information to design, manufacture or test of the Products; 

  

	 	c.	any injection molds, thermoforming molds, and any fixtures (“Tooling”) needed for or used in the production of the Products (“Product Tooling”) and that are
purchased by the Customer; and 

  

	 	d.	any inventions, ideas, discoveries, modifications, enhancements, improvements or derivative works conceived, made, created, developed or reduced to practice by Manufacturer, solely
or jointly, or in whole or in part, during the term of this Agreement that relate to the Products, Information or Product Tooling, or to any services provided under this Agreement (“Assigned Inventions”). 

 Manufacturer hereby irrevocably transfers and assigns to Customer all of Manufacturer’s right, title and interest in and to, and all Intellectual Property Rights
in, the Products, the Information, the Assigned Inventions and the Products Tooling (collectively, the “Assigned Rights”). In addition, the parties expressly agree to consider as works made for hire all copyrightable works included in the
Assigned Rights. Manufacturer agrees to execute any and all applications for domestic and foreign patents, copyrights or other proprietary rights and to do such other acts (including without limitation the execution and delivery of instruments of
further assistance or confirmation) requested by Customer to assign and permit the Customer to enforce the Assigned Rights. Manufacturer will not charge Customer for time spent in complying with these obligations. The Assigned Rights shall be kept
in confidence by Manufacturer and shall be used by Manufacturer only in performing this Agreement and may not be used by Manufacturer for other purposes except upon such terms as may be agreed upon between the parties in writing. 
 Manufacturer also agrees to acquire from its employees, agents and contractors, rights and covenants as to assure that Customer shall receive the rights provided for in
this section. Upon the termination of this Agreement, Manufacturer shall return to Customer or, in Customer’s discretion, destroy all Product Tooling in Manufacturer’s possession, custody, or control. 
  

 -2- 
 [*] =
Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. 

	3.2	Manufacturer Ownership. Other than Customer’s rights in the Assigned Rights provided for under Section 3.1 (which shall, in the event of a conflict, take precedence
over the rights of Manufacturer set forth in this section), Manufacturer shall exclusively own all right, title and interest in and to, and all Intellectual Property Rights related to: 

  

	 	a.	all know-how, technology, processes, procedures, ideas and concepts developed by Manufacturer for manufacturing products (“Manufacturer Processes”);

  

	 	b.	any modifications, enhancements, and improvements to the Manufacturer Processes created by Manufacturer during the term of this Agreement; and 

  

	 	c.	any non-Product specific Tooling created by Manufacturer during the term of this Agreement ((a), (b), and (c) collectively, “Manufacturer Rights”).

  

	3.3	Licenses. Customer hereby grants Manufacturer a non-exclusive, non-transferable, royalty-free fully paid license, with no right to sublicense, for the term of this Agreement
to use the Assigned Rights, but solely for the purpose of manufacturing and servicing the Products for Customer. Manufacturer hereby grants to Customer a non-exclusive, royalty-free, fully-paid license, with a right to sublicense, to use any
Manufacturer Rights necessary or useful for the manufacture or servicing of Products, and to make, have made and distribute the Products manufactured or serviced using said Manufacturer Rights. Upon request from Customer, Manufacturer shall provide
Customer with documents reasonably necessary for Customer to document and duplicate said Manufacturer Rights. 

  

	3.4	Customer Trademarks. Customer authorizes Manufacturer to affix and apply the Customer Trademarks to the Products as directed by Customer for the sole purpose of manufacturing
the Products pursuant to this Agreement. Manufacturer shall not use Customer Trademarks for any other purpose and only in such manner as to preserve all rights of Customer. Manufacturer acquires no right to Customer Trademarks by its use and all
uses by Manufacturer of the Customer Trademarks will inure to Customer’s sole benefit. As used herein, “Customer Trademarks” means those trademarks, trade names, service marks, slogans, designs, distinctive advertising, labels, logos,
and other trade-identifying symbols as are or have been developed and used by Customer or any of its subsidiaries or affiliate companies and which Customer owns or has the right to use. 

  

	4.	Term and Termination of the Agreement 

  

	4.1	Term. The term of this Agreement shall begin on the date first set forth above and shall continue under the conditions of Section 6 of this agreement, to the extent that
there are open purchase orders for medical devices as specified in attached Device Specific Schedule(s), or unless otherwise terminated earlier in accordance with the terms of this Agreement. 

  

	4.2	Termination for Cause by Either Party. This Agreement may be terminated by either Party immediately upon notice to the other party in the event of any of the following:

  

	 	a.	the other party makes a general assignment for the benefit of its creditors, or a receiver or similar officer is appointed to take charge of any of the other party’s assets;

  

 -3- 
 [*] =
Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. 

	 	b.	the other party ceases to carry on its business or operations; or 

  

	 	c.	a bankruptcy or similar petition is filed by or against the other party, and in the case of an involuntary petition, the proceeding is not dismissed within sixty (60) days.

  

	4.3	Termination for Material Breach. Upon material breach by either party of its obligations under this Agreement, the other party may terminate the Agreement if the breach
remains uncured for more than thirty (30) days after a party gives written notice of the breach, such notice to be effective upon the date of mailing. For purposes of a breach by Manufacturer, “material breach” includes without
limitation Manufacturer’s failure to satisfy its obligation to deliver the Product as specified in Customer’s purchase orders for three consecutive months. 

  

	4.4	Winding-Down Obligations. Following the expiration or termination of this Agreement, Manufacturer shall cooperate with Customer and provide reasonable assistance to effect
the orderly and efficient transfer of the manufacturing of Product from Manufacturer to the Customer or a third party designated by the Customer and without disruption to the Customer’s business (“Transfer Assistance”). Transfer
Assistance shall include, but not be limited to: (a) the continued manufacture of the Product by Manufacturer after the termination or expiration date for a transition period and on terms mutually agreeable to the parties; (b) the return
to Customer of all Products Specifications materials; (c) the transfer of all Products Inventory, Manufacturing Inventory, and other inventory for which Customer has compensated Manufacturer; (d) the transfer of any Product-specific
Tooling and equipment that has been purchased by the Customer; and (e) the transfer of any documents or electronic files relating to the manufacturing of the Product. The provisions of this Section 4.4 shall survive the termination or
expiration of this Agreement. Customer shall be responsible for any other costs incurred by Manufacturer in providing Transfer Assistance. 

  

	5.	Manufacturing Transfer 

  

	5.1	Manufacturer agrees to provide a detailed manufacturing transfer plan, subject to Customer approval, that will delineate all steps and milestones necessary to achieve market release
on the date noted in section 5 of Schedule A. 

  

	5.2	In addition to its other obligations under this Agreement, Manufacturer agrees to make every effort possible, including expedite of material and services from the supply chain, and
engineering and production work overtime, to mitigate delays in achieving transfer milestones on time. Unless delays are the result of design, material, or supply chain changes initiated by the Customer, all incremental costs for expediting
materials, services, engineering and production shall be the responsibility of Manufacturer. 

  

 -4- 
 [*] =
Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. 

	6.	Forecast, Purchase and Delivery of Finished Goods 

  

	6.1	All orders for the Product will be issued on the Customer’s monthly purchase order which is typically issued 3 months in advance of the expected dock date and represents a 90
day rolling commitment for finished devices. The Customer will also provide a rolling twelve-month forecast for the Manufacturer for planning and forecasting purposes only. Manufacturer shall acknowledge receipt of purchase orders from Customer as
soon as reasonably possible, but no later than three (3) business days following receipt. The Customer reserves the right to change or modify the monthly purchase orders or forecasts as needed. 

  

	6.2	The assembled, inspected, packaged and non-sterile Product shall be shipped F.O.B. to the sterilizer house: PCS in Taunton, MA. After sterilization, the “finished goods”
shall be shipped to the Customer’s inventory warehouse location in Dover, New Hampshire. Customer will pay costs of freight from Manufacturer to sterilizer and from sterilizer to warehouse. The carrier will be chosen at Customer discretion.

  

	6.3	At Customer’s request, costs for warehousing and direct distribution shall be quoted separately from this agreement. 

  

	6.4	Customer shall pay for finished goods no later than thirty (30) days after receipt of an invoice for shipping of finished goods provided the invoice date is no earlier than the
date of shipment to the sterilizer. 

  

	6.5	Customer agrees to pay interest on all invoiced amounts that are overdue more than 30 calendar days at the rate of 1.5% per month. Customer reserves the right to dispute an
invoice within 30 days of receipt and such disputed invoice will not be subject to the late interest charge provided that the reasons for the dispute are put into writing by Customer and that Customer and Manufacturer will make reasonable efforts to
resolve the dispute in a timely manner. 

  

	6.6	Manufacturer agrees to deliver finished goods to Customer’s sterilizer on time to achieve delivery of sterilized and released product to Customer’s warehouse per the
Customer’s purchase orders, or pay all incremental charges for premium freight, expedite fees to obtain raw material, and/or work production overtime to mitigate delays in receipt of finished goods to the Customer inventory location, in
addition to other remedies provided to Customer in Section 4.3, provided Manufacturer is responsible for the delays. 

  

	6.7	Manufacturer agrees to keep a minimum of three month’s worth of Customer identified ‘critical components’ in their inventory throughout the production run for these
products. Customer agrees to reimburse Manufacturer for component inventory in excess of the rolling forecast. The spirit of this clause is to provide an opportunity for the Customer and Manufacturer to jointly decide to capitalize on discounts due
to volume purchases while limiting the Manufacturer’s liability for carrying excess component inventories and also to minimize the impact of ‘critical component’ supply issues on the Customer’s production schedule.

  

 -5- 
 [*] =
Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. 

	7.	Quality System Requirements 

  

	7.1	Manufacturer shall obtain and maintain all registrations and approvals necessary to manufacture Customer’s Product. Manufacturer must remain compliant with the requirements set
forth in 21 U.S.C. § 360J (f), 21 C.F.R. § 820, all related guidance issued by the FDA, ISO 9001 and EN46001 (collectively, “Good Manufacturing Practices”). Manufacturer’s performance of this Agreement shall be in compliance
with these Good Manufacturing Practices. 

  

	7.2	Manufacturer agrees to permit Customer or its authorized representative, and government officials as required by law, to conduct inspections and test audits of Manufacturer’s
facilities, operations, and procedures, at appropriate and reasonable time intervals, to verify that the quality and performance of the Product produced by Manufacturer are in compliance with the Company’s Product Specifications. The Company
may also inspect the facilities of Manufacturer at any time during business hours to ensure compliance with Good Manufacturing Practices. Manufacturer shall cooperate with any inspection performed under this section. 

  

	7.3	Manufacturer agrees to make appropriate Manufacturer personnel available for audits at either Customer’s or Manufacturer’s offices. All reasonable expenses related to the
conduct of inspection and test audits of the Product and/or Quality System (as defined below in Section 7.6) by Customer or, if Customer so chooses, a qualified third party, that are directly and specifically related to Customer’s Product
shall be borne by Customer. Such audits and inspections must take place during normal business hours and with reasonable notice. 

  

	7.4	If the facilities or processes of Manufacturer are inspected or audited by any regulatory agency such as but not limited to the FDA, OHSA, EPA, or ISO Registrar, Manufacturer will
immediately inform Customer of that fact and of all findings of such agency that relate to or affect the Product or Device Master Record, which includes all information necessary to produce the Product. 

  

	7.5	Manufacturer shall maintain a complete and current Device Master Record for Customer’s Product. Copies of the Device Master Record shall be made available to Customer at
Customer’s request. Customer shall have the right from time to time to request that changes be made to the Device Master Record. Changes to the Device Master Record are to be communicated formally by the Customer’s change order and will be
subject to Manufacturer’s acceptance, which acceptance shall not be unreasonably withheld. The cost of the changes, and for implementing such changes, will be negotiated in good faith between the Customer and Manufacturer. Manufacturer shall
have no obligation to implement these changes until agreement on changes and prices have been reached. 

  

	7.6	Manufacturer shall maintain a quality system in accordance with ISO 90001, EN46001 certification and 21 CFR 820 Quality System Regulations compliance (“Quality System”).
All activities performed on behalf of Customer shall be performed in accordance with these regulations and standards. Manufacturer shall conduct manufacturing activities consistent with Customer’s Manufacturing Quality Plan. Manufacturer shall
maintain and retain Product quality related records, such as any records of system or instrument tests, for 5 years. 

  

 -6- 
 [*] =
Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. 

	7.7	Manufacturer shall allow Customer and government officials to perform audits of Manufacturer’s Quality System, Good Manufacturing Practices, facilities, records and all
manufacturing documentation related to Customer’s Product. 

  

	7.8	Manufacturer shall maintain a list of original component suppliers that they have approved (“Approved Suppliers”). Manufacturer shall purchase materials to be used in
Customer’s Product for sale only from Approved Suppliers. Approved Suppliers must have passed Manufacturer’s supplier evaluation process. If it has been determined by the Customer and Manufacturer that there is cause, Manufacturer shall
allow Customer to perform on-site audits of its Approved Suppliers, as requested, at mutually agreed upon times. Manufacturer shall assist the Approved Suppliers in providing corrective action to remedy any deficiencies observed during the audit,
and document such actions and outcomes to Customer. 

  

	7.9	Manufacturer shall obtain prior approval from Customer on all proposed changes including changes in approved suppliers, component materials, product labels, manufacturing and/or
test procedures, except for typographical errors, to the Product Specifications, Device Master Record, manufacturing procedures, or validated processes. Manufacturer shall also obtain prior approval on all deviations and NCMR’s that affect
product or component for, fit and/or function including discrepant materials that are dispositioned by the Manufacturer as ‘Use As Is’. Manufacturer agrees that all design change, approval, and revision control shall be consistent with
Good Manufacturing Practices and the Medical Device Directive, as published by the European Parliament. 

  

	7.10	Manufacturer agrees to comply with all additional terms and conditions specified in attached Device Specific Schedule(s). 

  

	8.	Tooling, Equipment, and Materials 

  

	8.1	Manufacturer will be reimbursed, at cost plus a margin not to exceed [*]%, for any equipment, Tooling and improvements to equipment and Tooling purchased by Manufacturer to perform
Manufacturer’s obligations to Customer. Manufacturer will be responsible for normal maintenance of Customer’s Tooling and equipment in its possession. Equipment and Tooling paid for by Customer remains the property of Customer, and shall
be returned to Customer in accordance with the provisions set forth in Sections 4.4 and 8. Expenditures greater that $1,000 (hereinafter “Substantive Expenditures”) for Tooling or equipment will be made only with prior written
authorization of Customer. Any Tooling or equipment requiring Substantive Expenditures for third party calibration or refurbishment will require Customer’s pre-approval and will be the financial responsibility of Customer if approved. In the
event Manufacturer is required to make a prepayment on Tooling or equipment, Customer will reimburse Manufacturer at the time the prepayment is made. 

  

 -7- 
 [*] =
Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. 

	8.2	At Customer’s request, Manufacturer shall provide Customer with a description and location of all Tooling and equipment (including original documentation relating to all
Tooling and equipment) held by Manufacturer or its subcontractors on behalf of Manufacturer. Customer has the right to inspect such Tooling and equipment at any time, during normal business hours and with reasonable notice, during the term of this
Agreement. Customer shall maintain property insurance covering all Customer Tooling and equipment held by Manufacturer, in amounts customary for companies of comparable size and type in similar industries. 

  

	8.3	On termination of this Agreement, Manufacturer agrees to deliver to Customer, FOB shipping point, all Tooling and equipment purchased and paid for by Customer, or at Customer’s
sole discretion, to implement alternative plans for disposition of Tooling and equipment as agreed to by Customer and Manufacturer or at Manufacturer’s subcontractors. 

  

	8.4	Any inventory (including finished goods, works in process, raw parts) or non-cancelable orders for such raw parts that is rendered excess or obsolete due to (a) the
cancellation of Customer’s purchase orders, (b) a permanent reduction in forecast that impacts any long lead time parts which are non-cancelable / non-returnable, (c) Engineering Change Orders (“ECO”), (d) minimum
quantity purchases of component parts, (e) end of Product life, (f) the termination of this Agreement, and which cannot be utilized on other Manufacturer product cannot be returned to Manufacturer’s Approved Suppliers, or
(g) documented restocking charges paid by Manufacturer to the Approved Supplier, will be the financial responsibility of Customer, at Manufacturer’s manufacturing cost (or in the case of parts, at actual cost) plus margin not to exceed
[*]%. 

  

	9.	Warranties 

  

	9.1	Manufacturer warrants to Customer that, on the date of delivery, the Product will conform to the Product Specifications as documented in the Device Master Record, and will be
produced in conformance with the Device Master Record in effect at the time of delivery. All other warranties, express or implied, including without limitation, warranties of merchantability and fitness for a particular purpose are hereby excluded.

  

	9.2	Within 90 days after receipt of any Product at the facility specified by Customer, Customer may reject any Product that it reasonably believes fails to meet the Product
Specifications by sending Manufacturer notice of the lot numbers of the rejected Product, together with an explanation of the specific basis for rejection. Customer shall within ninety (90) days of notification return to Manufacturer, any such
rejected Product. Appropriate credits are required when product is returned to the Manufacturer for proper accounting purposes on both sides of the relationship. Both Customer and Manufacturer agree that the issuance of a credit by the Manufacturer
will not be the sole indicator for determining Manufacturer’s culpability for the rejected product. 

  

 -8- 
 [*] =
Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. 

	9.3	Prior to any rejected product being returned to the Manufacturer, Customer and Manufacturer will reach mutual agreement regarding responsibility for the rejection, including any
reprocessing that may be required. Once agreement is reached, Manufacturer will generate an appropriate credit memo to Customer according to the following policy: 

 1. if it is agreed that the Manufacturer is responsible for the rejected product: 
  

	 	•	 	 Manufacturer will issue a credit memo for the original shipped quantity at the transfer price on the original invoice. 

  

	 	•	 	 The credit memo will clearly identify the rejected product as Manufacturer’s Responsibility and be accompanied by an RA # so the product can be properly
received back by the Manufacturer. 

  

	 	•	 	 Customer will put the original invoice on “hold” status until the product is reprocessed and a new invoice submitted. 

  

	 	•	 	 Manufacturer will develop a reprocessing plan jointly with Customer and reprocess the product as quickly as is practical. 

  

	 	•	 	 Upon shipment of the reprocessed product to the sterilizer, Manufacturer will invoice Customer for the net quantity shipped at the original transfer price.

  

	 	•	 	 Customer will balance the credit for the rejected product against the original invoice and agrees to pay an invoice for the reprocessed product on net
7 day terms to avoid any cash-flow issues at the Manufacturer. 

 2. If it is agreed that the Customer is
responsible for the rejected product: 
  

	 	•	 	 Customer will process the original invoice for payment on net 30 day terms as normal. 

  

	 	•	 	 Manufacturer will issue a credit memo for the net quantity that is to be returned to the Manufacturer at the transfer price on the original invoice.

  

	 	•	 	 The credit memo will clearly identify the rejected product as Customer’s Responsibility and be accompanied by an RA # so the product can be properly
received back by the Manufacturer. 

  

	 	•	 	 Manufacturer will develop a reprocessing plan jointly with Customer. Customer will authorize any reprocessing costs and Manufacturer agrees to reprocess the product
as quickly as is practical. 

  

 -9- 
 [*] =
Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. 

	 	•	 	 Upon shipment of the reprocessed product to the sterilizer, Manufacturer will invoice Customer for the net quantity shipped (plus any attrition from the
reprocessing effort) at the original transfer price + the reprocessing cost. 

  

	 	•	 	 Customer will balance the credit for the rejected product against the new invoice and agrees to pay any balance due (reprocessing costs) on net 30 day
terms. 

  

	10.	Indemnification 

  

	10.1	Manufacturer shall defend, indemnify, and hold Customer, its officers, directors, employees, and agents harmless against any and all claims, demands, proceedings, losses, damages,
obligations, liabilities, deficiencies, fines, costs, or expenses (including, without limitation, reasonable attorneys’ fees) (collectively, “Losses”) arising directly or indirectly as a result of, or relating to, (a) any
material breach of this Agreement by Manufacturer or its officers, trustees, employees, or agents; (b) any negligence by Manufacturer in the manufacture of the Product or any failure to manufacture the Product in accordance with the Product
Specifications; or (c) any negligence or wrongful acts of Manufacturer or its officers, trustees, employees, or agents, except to the extent that any such Losses are due to the negligence or wrongful acts of Customer, its officers, trustees,
employees, or agents. 

  

	10.2	Customer shall defend, indemnify, and hold Manufacturer, its officers, directors, employees, and agents harmless against any and all Losses arising directly or indirectly as a
result of, or relating to (a) defects in the Product Specifications, or (b) Manufacturer’s complying with the Product Specifications, except to the extent that any such Losses are due to the negligence or wrongful acts of the
Manufacturer, its officers, trustees, employees, or agents. 

  

	11.	Insurance 

  

	11.1	Coverage. Manufacturer shall maintain the following insurance during the term of this Agreement. 

  

	 	a.	Commercial General Liability, including blanket contractual liability, broad form property damage, product made under manufacturing agreement and completed operations, independent
contractors and premises/operations, in amounts of not less than $1 million per occurrence, $2 million in aggregate. 

  

	 	b.	Comprehensive Automobile Liability, including owned, non-owned and hired vehicles, in amounts of not less than $1 million per occurrence. 

  

	 	c.	Worker’s Compensation Insurance in amounts of not less than $500,000 per occurrence. 

  

	11.2	 General. The above insurance shall be issued by an insurance company licensed to do business in New Hampshire with an A.M. Bests rating of A or better, and
include Customer as an “additional insured” on all policies except Worker’s Compensation, and 

  

 -10- 
 [*] =
Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. 

	 	 
shall provide that Customer will receive thirty (30) days written notice from the insurer prior to any cancellation or change of coverage provided that
comparable insurance is not purchased from another carrier. Manufacturer shall deliver certificates of insurance evidencing such coverage to Customer on or before the Effective Date, and thereafter at least fifteen (15) days before the
expiration dates of expiring policies. 

 11.3 Manufacturer shall provide Customer a Certificate of Insured within 10 days of acceptance of
this agreement. 
  

	12.	Field Failures and Recalls 

  

	12.1	Customer and Manufacturer agree to notify the other party if applicable when notified of a Product failure in the field. Each party shall provide the other with documentation
supporting the occurrence of a Product failure. Both parties shall work together to: (a) determine if a failure condition actually exists, and (b) if one does, devise a comprehensive plan for responding to the condition that may include
corrective and preventive actions. 

  

	12.2	Manufacturer and Customer each agree to notify the other if applicable whenever it believes the Product is or may be subject to recall. Customer shall determine whether a recall or
other corrective action is necessary, and determine whether to cease shipping and manufacturing the Product. If a recall or other corrective action is necessary, the parties will work together to develop a recall or corrective action plan.

  

	12.3	If any Product recall or field correction is initiated, up to 180 days from Customer’s acceptance of Product from Manufacturer, because of the negligence of Manufacturer or a
defect in any product arising primarily from any breach of Manufacturer of any warranty, representation, or other obligation contained in this Agreement, Manufacturer will, in addition to any other remedies available to Customer under this
Agreement, (a) credit to Customer the price paid by Customer with respect to the Product purchased from Manufacturer, including any shipping expenses and freight insurance; (b) reimburse Customer for out-of-pocket costs actually paid by
Customer and/or its designee to third parties for transportation and destruction of the recalled Product, and for reasonable out-of-pocket communications expenses (exclusive of mass media expenses) associated with such recall.

  

	12.4	Recall or corrective action that is necessary due to a defect in the Product design shall be made at Customer’s expense. 

  

	12.5	To assist Customer in diagnosing and resolving Product failures in the field, Manufacturer agrees to provide technical support for up to two years after Customer’s sale of
Product manufactured under this Agreement. Technical support includes review of related inspection, manufacturing, sterilization, test, and release records. 

  

 -11- 
 [*] =
Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. 

	13.	Limitation of Liability 

  

	13.1	EXCEPT AS SET FORTH OTHERWISE IN THIS AGREEMENT, IN NO EVENT SHALL EITHER PARTY BE LIABLE TO THE OTHER FOR ANY INCIDENTAL, CONSEQUENTIAL, SPECIAL OR PUNITIVE DAMAGES OF ANY KIND OR
NATURE ARISING OUT OF THIS AGREEMENT OR THE SALE OF PRODUCT, WHETHER SUCH LIABILITY IS ASSERTED ON THE BASIS OF CONTRACT, TORT (INCLUDING THE POSSIBILITY OF NEGLIGENCE OR STRICT LIABILITY), OR OTHERWISE, EVEN IF THE PARTY HAS BEEN WARNED OF THE
POSSIBILITY OF ANY SUCH LOSS OR DAMAGE, AND EVEN IF ANY OF THE LIMITED REMEDIES IN THIS AGREEMENT FAIL OF THEIR ESSENTIAL PURPOSE. 

  

	14.	Confidentiality 

  

	14.1	Confidential Information. “Confidential Information” includes any and all information of or about a party including all information relating to any technology,
product, process or intellectual property of such party (including, but not limited to, owned or licensed intellectual property rights, data, know-how, samples, technical and non-technical materials and specifications) as well as any business plan,
financial information or other confidential commercial information of or about such party. Notwithstanding the foregoing, information of or about a party shall not be considered Confidential Information with respect to such party to the extent that
the party possessing such information can demonstrate by written record or other suitable physical evidence that: 

  

	 	a.	such information was lawfully in such party’s possession or control prior to the time such information was disclosed to the party by the other party to whom the information
relates; 

  

	 	b.	such information was developed by such party independently of and without reference to Confidential Information; 

  

	 	c.	such information was lawfully obtained by such party from a third party under no obligation of confidentiality to the other party to whom such information relates; or

  

	 	d.	such information was at the time it was disclosed or obtained by such party, or thereafter became, publicly known otherwise than through a breach by such party of such party’s
obligations to the other party to whom such information relates. 

  

	14.2	 Non-Disclosure. Each party shall maintain the Confidential Information of the other party in confidence by using the same degree of care (but no less than a
reasonable degree of care) that such party maintains and protects its own Confidential Information, and shall not disclose, divulge, or otherwise communicate such Confidential Information to others, or use it for any purpose, except pursuant to, and
in order to carry out, the terms and objectives of this Agreement or with the express written consent of the party who provided such Confidential Information. Each party also hereby agrees to take reasonable steps to prevent and restrain the
unauthorized disclosure of such Confidential Information by any of its directors, officers, employees, 

  

 -12- 
 [*] =
Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. 

	 	 
consultants, sub-contractors, sub-licensees or agents. The provisions of this paragraph shall not apply to any Confidential Information of a party which is
required to be disclosed by another party to comply with any applicable laws or regulations, but only to the extent required by such law or regulation and further provided that the party making any disclosure pursuant to the provisions of this
sentence shall provide prior written notice of such disclosure to the other party sufficiently in advance of such disclosure to allow such other party to respond and to take reasonable and lawful action to avoid and/or minimize the degree of such
disclosure. 

  

	14.3	No Confidential Information of Other Parties. Each party represents and warrants to the other that it has not used and shall not use in the course of its performance
hereunder, and shall not disclose to the other, any Confidential Information of any third party, unless it is expressly authorized in writing by such third party to do so. 

  

	15.	Successors, Assignment 

  

	15.1	This Agreement shall be binding upon and inure to the benefit of the parties hereto and their respective successors, assigns and legal representatives. Neither party shall have the
right to assign or otherwise transfer its rights or obligations under this Agreement in whole or in part to any third party without the prior written consent of the other party. Nothing in this section shall prohibit Customer from assigning this
Agreement to an entity acquiring all or substantially all of the business of Customer. In addition, Manufacturer may assign this Agreement to an entity acquiring all or substantially all of the business of Manufacturer, provided that such assignee
is capable of fulfilling the obligations of the Manufacturer set forth in this Agreement. Each party will notify the other in writing within 60 days of any material change in ownership or assignment. 

  

	16.	Miscellaneous 

  

	16.1	Compliance with Laws and Permitting. Each party agrees that its performance under this Agreement shall comply with all applicable laws. Manufacturer shall, at its expense,
obtain and maintain all necessary permits and licenses required for the operation of its manufacturing facilities and processes. 

  

	16.2	Force Majeure. In the event that either party is prevented from performing or is unable to perform any of its obligations under this Agreement (other than a payment
obligation) due to any Act of God, fire, casualty, flood, earthquake, war, strike, lockout, epidemic, destruction of production facilities, riot, insurrection, or any other cause beyond the reasonable control of the party invoking this section, and
if such party shall have used its commercially reasonable efforts to mitigate its effects, such party shall give prompt written notice to the other party, its performance shall be excused, and the time for the performance shall be extended for the
period of delay or inability to perform due to such occurrences. Regardless of the excuse of Force Majeure, if such party is not able to perform within ninety (90) days after such event, the other party may terminate the Agreement. Termination
of this Agreement shall not affect the obligations of either party, which exist as of the date of termination. 

  

 -13- 
 [*] =
Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. 

	16.3	Export Controls. Manufacturer shall comply will all United States and any applicable foreign laws and regulations governing the export of technology and Product. Customer and
Manufacturer shall cooperate with one another, including providing all required documentation and information, to obtain all necessary government authorizations before exporting any technology or Product under this Agreement.

  

	16.4	Governing Law. This Agreement shall be governed by and interpreted under the laws of the State of New Hampshire without regard to conflict of law provisions.

  

	16.5	Notices. All notices required or permitted under this Agreement must be made in writing and delivered in person, by facsimile, or by certified or registered mail, postage
prepaid, addressed to Jon Wilson, VP of Product Development for Customer, or Eric Crainich, President of Operations for Manufacturer, at the respective addresses at the beginning of this Agreement. Such notice shall be effective upon receipt
if personally delivered or transmitted by facsimile, or on the third business day following the date of mailing. 

  

	16.6	Amendments. This Agreement may be amended only by written consent of both parties, executed by their authorized representatives. 

  

	16.7	Severability. Any provision of this Agreement, which is invalid or unenforceable in any jurisdiction, shall, as to such jurisdiction, be ineffective to the extent of such
invalidity or unenforceability without rendering invalid or unenforceable the remaining terms and provisions of this Agreement in any other jurisdiction. 

  

	16.8	Dispute Resolution. All disputes arising between the parties that are not resolved to the parties’ reasonable satisfaction shall be submitted to non-binding arbitration
before the American Arbitration Association, pursuant to the rules of the American Arbitration Association. 

  

	16.9	Headings. Headings contained in this Agreement are for convenience and reference purposes only and shall not affect the meaning or interpretation of this Agreement. The
Attachments to this Agreement are incorporated by reference into this Agreement and form an integral part thereof. 

  

	16.10 	Subcontracting. This Agreement is for the exclusive benefit of Customer and Manufacturer and is not for the benefit of any third party. Manufacturer shall not have the rights
to sub-contract the performance of any of its obligations under this Agreement without the express written consent of Customer. 

  

	16.11 	Counterparts. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original and all of which together shall constitute one instrument.

  

 -14- 
 [*] =
Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. 

 IN WITNESS WHEREOF, the parties hereto have as of the date first written above duly executed this General
Agreement, including the attached Device Specific Schedule(s) that are incorporated herein and made a part hereof. 
  

									
	TISSUELINK MEDICAL, INC.	 		 	DESIGN STANDARDS CORPORATION
					
	By:	 	/s/ Jon Wilson	 		 	By:	 	/s/ Illegible
	Name:	 	Jon Wilson	 		 	Name:	 	Illegible
	Title:	 	VP Development	 		 	Title:	 	President

  

 -15- 
 [*] =
Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. 

 Contract Amendment #1 
 On October 1, 2007 the following amendment will void, cancel and replace Section 6.1 and Section 6.7 in the Contract Manufacturing General Agreement between TissueLink Medical Inc. and Design Standards
Corporation entered into on November 10, 2004. 
  

	1.	TissueLink Medical agrees to extend the current rolling three months worth of purchase orders to a rolling six months worth of purchase orders. 

  

	 	a)	The first three months of the rolling six months worth of purchase orders is firm. Any changes requested in delivery by TissueLink Medical are subject to availability as determined
by Design Standards. 

  

	 	b)	The next three months worth of purchase orders are flexible and can be rescheduled, but not cancelled, unless some unforeseen business issue arises (for example: product recall,
quality issues, market changes, etc.) 

  

	2.	Design Standards must acknowledge pricing and delivery on all purchase orders issued by TissueLink Medical in writing within three days of their release. 

 

	3.	Requests from Design Standards to reschedule previously acknowledged delivery dates or delivery quantities must be made in writing to TissueLink Medical a minimum of sixty days
prior to the previously acknowledged delivery date or delivery quantity. 

  

	4.	Product pricing is to remain unchanged for the open six months worth of purchase orders. 

  

	5.	TissueLink Medical will monitor, track and report on Design Standards delivery performance. TissueLink Medical’s goal for on-time delivery from Design Standards is 90% or
higher. TissueLink Medical’s quality goal from Design Standards is 95% or higher first pass yield. 

  

	6.	TissueLink Medical and Design Standards are to perform a monthly comparison of open purchase orders to ensure that both companies are in agreement with the open order status (for
example: pricing, order quantity, promised delivery dates, etc.). Any discrepancies in information should be reported by Design Standards in writing within three business days of the release of a new open order report by TissueLink Medical.

  

	7.	If due to engineering changes, business changes, market changes, or any other unforeseen business reason, TissueLink Medical discontinues the need for any component or finished
device, TissueLink Medical will only be responsible for the individual value of component inventory up to two times the amount required for the open six months worth of purchase orders. 

 The inventory calculation for TissueLink Medical’s responsibility does not include any unfulfilled past due purchase orders. The inventory
calculation for TissueLink Medical’s responsibility is not an aggregate amount of the total Design Standards component inventory, but a total not to exceed two times the value of each individual component required to support the production of
the open six months worth of purchase orders released to Design Standards. 
  

 [*] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of
this exhibit has been filed separately with the Commission. 

	8.	Any individual component inventory that does not meet the guidelines outlined in Item 7 listed above will remain the financial responsibility of Design Standards.

  

	9.	TissueLink Medical must make payment for discontinued or obsolete component inventory identified by Design Standards that is agreed to and confirmed by TissueLink within thirty days
of the confirmation. 

 IN WITNESS WHEREOF, the parties hereto have as of the date written above duly executed this Amendment, including the
Contract Manufacturing General Agreement that are incorporated herein and made a part hereof. 
  

									
	TISSUELINK MEDICAL, INC.	 		 	DESIGN STANDARDS CORP.
					
	By:	 	/s/ Ted Vaughn	 		 	By:	 	/s/ Illegible
	Name:	 	Ted Vaughn	 		 	Name:	 	Illegible
	Title:	 	VP Operations	 		 	Title:	 	President

  

 [*] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of
this exhibit has been filed separately with the Commission.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00141-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00141-of-00352.parquet"}]]